Cardiotoxicity of novel HER2-targeted therapies

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.8, 2013-08, pp. : 1015-1024

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

CANCER, Vol. 122, Iss. 17, 2016-09 ,pp. : 2654-2662

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeted HER2 Treatment in Advanced Gastric Cancer

Oncology, Vol. 78, Iss. 1, 2010-02 ,pp. : 26-33

Karger

Access to resources Recommend Favorite

Targeted Therapy in HER2-Positive Breast Cancer

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Targeted Therapy of HER2-Negative Breast Cancer

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite

Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?

Reviews on Recent Clinical Trials, Vol. 10, Iss. 2, 2015-01 ,pp. : 82-89

Bentham Science Publishers

Access to resources Recommend Favorite